Radical Prostatectomy and External Beam Radiotherapy in mCRPC With 223Radium-dicloride (RaProRad)
Radical Prostatectomy and External Beam Radiotherapy in mCRPC With 223Radium-dicloride (RaProRad)
The investigators provided a multicenter analysis aiming to investigate, in a clinical
 practice setting, the prognostic relevance of previous primary radical prostatectomy (RP) or
 external beam radiotherapy (RT) in terms of Overall Survival as opposed to patients with no
 primary treatment performed, in a cohort of patients enrolled in 223-Ra treatment for mCRPC.
 223-Ra has been administered from investigators according to the current label authorization
 and all patients underwent 223-Ra treatment, until disease progression or unacceptable
 toxicity.
Inclusion Criteria:

 -  histological confirmation of prostatic adenocarcinoma, at least two symptomatic bone
 secondary lesions detected by bone scan and no known visceral metastases, except for
 malignant lymphadenopathy with less than 3 cm in the short axis diameter

 Exclusion Criteria:

 -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) score >2 and
 inadequate hematological, hepatic and renal function